|
시장보고서
상품코드
1983198
주의력 결핍 과잉행동 장애(ADHD) 치료제 시장 : 약제 유형별, 연령층별, 유통 채널별, 지역별Attention Deficit Hyperactivity Disorder Treatment Market, By Drug Type, By Age Group, by Distribution Channel, By Geography |
||||||
주의력 결핍 과잉행동 장애(ADHD) 치료제 시장은 2026년에 265억 5,700만 달러로 추정되고 있으며, 2033년까지 429억 4,300만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 7.1%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 265억 5,700만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 7.10% | 2033년 시장 규모 예측 : | 429억 4,300만 달러 |
세계 주의력결핍 및 과잉행동장애(ADHD) 치료제 시장은 주의력결핍 및 과잉행동장애 치료에 사용되는 치료제로 구성되어 있습니다. 치료제에는 암페타민, 메틸페니데이트, 덱스트로암페타민, 덱스트로암페타민, 덱스메틸페니데이트, 리스덱삼페타민디메실레이트 등의 자극제와 아목시탐페타민, 부프로피온, 구안화신, 클로니딘 등의 비자극제 등 다양한 유형의 약물이 있습니다. 주의력결핍-과잉행동장애(ADHD)는 주로 부주의형, 주로 과잉행동-충동형, 혼합형 등 세 가지 유형으로 나뉩니다. 주의력 결핍 및 과잉행동장애(ADHD)의 다양한 원인으로는 뇌손상, 임신 중 알코올 및 담배 섭취, 조산, 저체중아 출산 등이 있습니다. 이는 수백만 명의 어린이에게 영향을 미치는 만성질환으로, 성인기까지 지속되는 경우가 많습니다. 주의력결핍-과잉행동장애(ADHD)를 가진 아이들은 종종 낮은 자존감과 학교 성적 부진으로 어려움을 겪습니다. 주의력결핍-과잉행동장애(ADHD)는 완치될 수 없지만, 증상에 대한 대처는 가능합니다. ADHD의 치료에는 약물 치료와 더불어 행동치료가 병행됩니다. ADHD의 주요 증상은 부주의입니다. ADHD는 유전 등의 요인이 복합적으로 작용하여 발생한다고 알려져 있으며, 연구자들은 ADHD 발병 위험을 증가시킬 수 있는 환경적 요인을 조사하는 한편, 뇌 손상, 영양, 사회 환경이 ADHD에 어떤 역할을 하는지에 대한 연구를 진행하고 있습니다.
시장 역학
주요 기업은 전 세계 주의력결핍 및 과잉행동장애(ADHD) 치료제 시장에서 입지를 강화하기 위해 기술 혁신에 집중하고 있습니다. 예를 들어 2020년 6월 디지털 의약품 처방 기업 Akili Interactive Labs는 미국 식품의약국(FDA)으로부터 주의력 결핍 및 과잉행동장애(ADHD) 아동용 처방약 치료제인 EndeavorRxTM(AKL-T01)에 대한 승인을 획득했습니다. EndeavorRxTM는 ADHD를 앓고 있는 아이들의 주의력을 치료하고 개선하는 데 사용됩니다.
이 보고서의 주요 특징
- 세계의 주의력결핍 및 과잉행동장애(ADHD) 치료제 시장을 상세하게 분석했으며, 2025년을 기준 연도로 하여 예측 기간(2026-2033년) 시장 규모와 CAGR을 조사하여 전해드립니다.
- 또한 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트을 제공합니다.
- 세계 주의력결핍 및 과잉행동장애(ADHD) 치료제 시장의 주요 기업 개요을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 분석합니다.
- 이 보고서의 인사이트을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 주의력 결핍 및 과잉행동장애(ADHD) 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 주의력결핍 및 과잉행동장애(ADHD) 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 주의력 결핍 과잉행동 장애(ADHD) 치료제 시장 : 약제 유형별(2026-2033년)
제5장 세계의 주의력 결핍 과잉행동 장애(ADHD) 치료제 시장 : 연령층별(2026-2033년)
제6장 세계의 주의력 결핍 과잉행동 장애(ADHD) 치료제 시장 : 유통 채널별(2026-2033년)
제7장 세계의 주의력 결핍 과잉행동 장애(ADHD) 치료제 시장 : 지역별(2026-2033년)
제8장 경쟁 구도
제9장 섹션
KSA 26.04.20Attention Deficit Hyperactivity Disorder Treatment Market is estimated to be valued at USD 26,557 Mn in 2026 and is expected to reach USD 42,943 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 26,557 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.10% | 2033 Value Projection: | USD 42,943 Mn |
The global attention deficit hyperactivity disorder (ADHD) treatment market comprises therapeutics used for the treatment of attention deficit hyperactivity disorder. There are various therapeutics such as stimulants, which include stimulant drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate and non-stimulant drugs such as Atomoxetine, Bupropion, Guanfacine, and Clonidine. There are three types of attention deficit hyperactivity disorder (ADHD) such as predominantly inattentive presentation, predominantly hyperactive-impulsive presentation, and combined presentation. Various causes of attention deficit hyperactivity disorder (ADHD) include brain injury, alcohol and tobacco use during pregnancy, premature delivery, and low birth weight. It is a chronic condition which affects millions of children and often continue until the adulthood. Children with attention deficit hyperactivity disorder often suffer and struggle with low self-esteem and poor performance in school. Attention deficit hyperactivity disorder are not curable but can deal with symptoms. Treatment of attention deficit hyperactivity disorder involves medications as well as behavioral intervention. ADHD mainly have symptoms of inattention. ADHD probably results from a combination of factors such as genetics, researchers are looking at possible environmental factors that might raise the risk of developing ADHD and are studying how brain injuries, nutrition, and social environments might play a role in ADHD.
Market Dynamics
Key players are focusing on technological advancements to strengthen their position in the global attention deficit hyperactivity disorder (ADHD) treatment market. For instance, in June 2020, Akili Interactive Labs, a digital medicine prescription company received the U.S. Food Drug and Administration clearance for EndeavorRxTM (AKL-T01), a prescription medicine treatment for children with attention deficit hyperactivity disorder (ADHD). EndeavorRxTM is used to treat and to improve attention in children suffering from ADHD.
Key features of the study
- This report provides an in-depth analysis of the global attention deficit hyperactivity disorder treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global attention deficit hyperactivity disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Amnel Pharmaceuticals LLC., Eli Lilly And Company, Johnson & Johnson Services, Inc., Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Purdue Pharma L.P. ,Cingulate, Adlon Therapeutics L.P., Tris Pharma, Inc.,Neuraxpharm, Supernus Pharmaceuticals,Inc., and Aytu Biopharma, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global attention deficit hyperactivity disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global attention deficit hyperactivity disorder treatment market
Market Segmentation
- Drug Type Insights (Revenue, USD Mn, 2026 - 2033)
- Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine Dimesylate
- Non-stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine
- Age Group Insights (Revenue, USD Mn, 2026 - 2033)
- Pediatric and Adolescent
- Adult
- Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Amnel Pharmaceuticals LLC.
- Eli Lilly And Company
- Johnson & Johnson Services, Inc.
- Noven Pharmaceuticals, Inc
- RespireRx Pharmaceuticals Inc
- Otsuka Pharmaceutical Co. Ltd
- Neos Therapeutics, Inc.
- American Brivision (Holding) Corporation
- Novartis AG
- Takeda Pharmaceutical Company Limited
- GSK plc
- Purdue Pharma L.P.Cingulate
- Adlon Therapeutics L.P.
- Tris Pharma, Inc.
- Neuraxpharm
- Supernus Pharmaceuticals, Inc.
- Aytu Biopharma, Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Age Group
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Regulatory Scenario
- Pricing Analysis
- Brand Mapping
- Pipeline Analysis
- PEST Analysis
4. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Drug Type, 2026-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Stimulants
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine Dimesylate
- Non-Stimulants
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine
5. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Age Group, 2026-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pediatric and Adolescent
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adult
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Distribution Channel, 2026-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Online Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
7. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Region, 2026-2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Type, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Age Group, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Amnel Pharmaceuticals LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly And Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Noven Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- RespireRx Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Neos Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- American Brivision (Holding) Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GSK plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Purdue Pharma L.P.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cingulate
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Adlon Therapeutics L.P.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Tris Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Neuraxpharm
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Supernus Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Aytu Biopharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
